Balyasny Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Balyasny Asset Management’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-327,045	Closed	-$15.7M	–	1648
2020 Q1	$15.7M	Buy	327,045 +135,708	+71%	+$6.31M	0.19%	160
2019 Q4	$8.98M	Buy	+191,337	New	+$8.46M	0.05%	452
2018 Q2	–	Sell	-28,997	Closed	-$154K	–	2327
2018 Q1	$154K	Sell	28,997 -4,703	-14%	-$33.6K	﹤0.01%	1795
2017 Q4	$286K	Buy	+33,700	New	+$414K	﹤0.01%	1766
2017 Q2	–	Sell	-14,170	Closed	-$302K	–	1885
2017 Q1	$302K	Buy	14,170 +590	+4%	+$11.3K	﹤0.01%	1406
2016 Q4	$206K	Buy	+13,580	New	+$185K	﹤0.01%	1282

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Balyasny Asset Management's RARX Position: Q2 2020 in Review

Balyasny Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 327,045 shares — an estimated $15.7M sold.

Balyasny Asset Management first reported a position in RARX in Q4 2016 and held it in 6 quarters. The position peaked at $15.7M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Balyasny Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Balyasny Asset Management sold 327,045 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $15.7M.
Balyasny Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 6 quarters.
Balyasny Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $15.7M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Balyasny Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.